NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.

ABSTRACT:

Background

Activating fusions of the NTRK1, NTRK2 and NTRK3 genes are drivers of carcinogenesis and proliferation across a broad range of tumour types in both adult and paediatric patients. Recently, the FDA granted tumour-agnostic approvals of TRK inhibitors, larotrectinib and entrectinib, based on significant and durable responses in multiple primary tumour types. Unfortunately, testing rates in clinical practice remain quite low. Adding plasma next-generation sequencing of circulating tumour DNA (ctDNA) to tissue-based testing increases the detection rate of oncogenic drivers and demonstrates high concordance with tissue genotyping. However, the clinical potential of ctDNA analysis to identify NTRK fusion-positive tumours has been largely unexplored.

Methods

We retrospect

SUBMITTER: Rolfo C 

PROVIDER: S-EPMC8811064 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature